Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
April 24, 2024 00:30 ET
|
Novartis Pharma AG
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic...
LSU Researchers' Nootkatone Studies Could Lead to Prevention of Lyme Disease
April 09, 2024 10:00 ET
|
LSU College of Engineering
BATON ROUGE, La., April 09, 2024 (GLOBE NEWSWIRE) -- Thanks to a $550,000 National Science Foundation Partnership for Innovation grant—the largest NSF PFI grant ever awarded to LSU—LSU Chemical...
Global Infectious Disease Diagnostics Market Set for Remarkable Growth, Driven by Advances in PoC and DNA Sequencing Technologies
March 21, 2024 12:51 ET
|
Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Global Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology...
Malaria Treatment Market Size to Hit 28.5% CAGR, Globally, by 2030 - Exclusive Report by The Insight Partners
November 03, 2023 08:38 ET
|
The Insight Partners
Pune, India, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Malaria is a serious infection spread by an infected mosquito. The infection is very common in certain parts of the world, such as large areas of...
Malaria and Sickle Cell Disease Treatment Market Worth $29.17 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
November 03, 2023 08:33 ET
|
The Insight Partners
Pune, India, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Sickle cell disease (SCD) is the most common inherited blood disorder that affects the red blood cells. Treatments for SCD can relieve pain and help...
Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa
September 15, 2023 12:48 ET
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., Sept. 15, 2023 (GLOBE NEWSWIRE) -- A Purdue researcher is taking a giant leap forward in the fight against drug-resistant strains of malaria in developing countries. Open...
Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.
September 14, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Presentation will be hosted live on Ocean Biomedical’s Youtube Channel at 2:00pm ET Providence, RI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next-generation...
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
August 22, 2023 07:31 ET
|
Sixty Degrees Pharmaceuticals
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individualsTafenoquine...
Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers
August 10, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr. Jonathan Kurtis, MD, PhD on September 14, 2023 Providence, RI,...
Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.
August 09, 2023 08:31 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr. Jonathan Kurtis, MD, PhD on September 14, 2023 Providence, RI, Aug. ...